AU2017334035B2 - Treatment of prostate cancer - Google Patents

Treatment of prostate cancer Download PDF

Info

Publication number
AU2017334035B2
AU2017334035B2 AU2017334035A AU2017334035A AU2017334035B2 AU 2017334035 B2 AU2017334035 B2 AU 2017334035B2 AU 2017334035 A AU2017334035 A AU 2017334035A AU 2017334035 A AU2017334035 A AU 2017334035A AU 2017334035 B2 AU2017334035 B2 AU 2017334035B2
Authority
AU
Australia
Prior art keywords
oral
administration
once
disclosure
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017334035A
Other languages
English (en)
Other versions
AU2017334035A1 (en
Inventor
Brendan Mark JOHNSON
David B. Maclean
Paul N. Mudd Jr.
Vijaykumar Reddy RAJASEKHAR
Lynn Seely
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Switzerland GmbH
Takeda Pharmaceutical Co Ltd
Original Assignee
Sumitomo Pharma Switzerland GmbH
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017334035(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Co Ltd filed Critical Sumitomo Pharma Switzerland GmbH
Publication of AU2017334035A1 publication Critical patent/AU2017334035A1/en
Application granted granted Critical
Publication of AU2017334035B2 publication Critical patent/AU2017334035B2/en
Priority to AU2023201047A priority Critical patent/AU2023201047B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED, SUMITOMO PHARMA SWITZERLAND GMBH reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request to Amend Deed and Register Assignors: MYOVANT SCIENCES GMBH, TAKEDA PHARMACEUTICAL COMPANY LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017334035A 2016-09-30 2017-09-29 Treatment of prostate cancer Active AU2017334035B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023201047A AU2023201047B2 (en) 2016-09-30 2023-02-22 Treatment of prostate cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662402004P 2016-09-30 2016-09-30
US201662402150P 2016-09-30 2016-09-30
US62/402,150 2016-09-30
US62/402,004 2016-09-30
PCT/EP2017/074849 WO2018060463A2 (en) 2016-09-30 2017-09-29 Treatment of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023201047A Division AU2023201047B2 (en) 2016-09-30 2023-02-22 Treatment of prostate cancer

Publications (2)

Publication Number Publication Date
AU2017334035A1 AU2017334035A1 (en) 2019-05-16
AU2017334035B2 true AU2017334035B2 (en) 2022-11-24

Family

ID=60915459

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017334035A Active AU2017334035B2 (en) 2016-09-30 2017-09-29 Treatment of prostate cancer
AU2023201047A Active AU2023201047B2 (en) 2016-09-30 2023-02-22 Treatment of prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023201047A Active AU2023201047B2 (en) 2016-09-30 2023-02-22 Treatment of prostate cancer

Country Status (21)

Country Link
US (8) US10449191B2 (enExample)
EP (2) EP3518932B1 (enExample)
JP (1) JP7062673B2 (enExample)
CN (1) CN110248661A (enExample)
AU (2) AU2017334035B2 (enExample)
BR (1) BR112019006228A2 (enExample)
CA (1) CA3038875A1 (enExample)
DK (1) DK3518932T3 (enExample)
ES (1) ES3002857T3 (enExample)
FI (1) FI3518932T3 (enExample)
HR (1) HRP20241740T1 (enExample)
HU (1) HUE070578T2 (enExample)
IL (3) IL308528A (enExample)
LT (1) LT3518932T (enExample)
MA (1) MA46361A (enExample)
MX (2) MX2019003733A (enExample)
NZ (1) NZ752918A (enExample)
PL (1) PL3518932T3 (enExample)
PT (1) PT3518932T (enExample)
SI (1) SI3518932T1 (enExample)
WO (1) WO2018060463A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190729T1 (hr) 2012-09-28 2019-06-14 Takeda Pharmaceutical Company Limited Metoda proizvodnje derivata tienopirimidina
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
EP3518932B1 (en) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Treatment of prostate cancer
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
EP4041738A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN115279769A (zh) * 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
AU2021278303A1 (en) 2020-05-29 2023-02-09 Sumitomo Pharma Switzerland Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
US20230384316A1 (en) * 2020-10-20 2023-11-30 Baylor College Of Medicine Multiplex metabolic markers in plasma for early detection of african american prostate cancer
EP4243829A1 (en) * 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2023152611A1 (en) * 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
AU2001234188A1 (en) 2000-02-29 2001-09-12 Takeda Chemical Industries Ltd. Processes for the production of thienopyrimidine derivatives
US20050043315A1 (en) 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
WO2003064429A1 (en) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
DK1480679T3 (da) 2002-02-26 2007-09-03 Astrazeneca Ab Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat
KR101074462B1 (ko) 2003-01-29 2011-10-18 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 화합물 및 그 용도
KR101139148B1 (ko) 2003-07-07 2012-04-26 뉴로크린 바이오사이언시즈 인코퍼레이티드 고나도트로핀-방출 호르몬 수용체 길항제로서의피리미딘-2,4-디온 유도체
NZ566038A (en) 2005-07-22 2011-06-30 Takeda Pharmaceutical The use of thieno(2,3-d)pyrimidine-2,4-dione derivatives which are gonadotropin releasing hormone (GnRH) antagonists as premature ovulation preventive agent
ES2534573T3 (es) 2007-04-06 2015-04-24 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
HRP20190729T1 (hr) 2012-09-28 2019-06-14 Takeda Pharmaceutical Company Limited Metoda proizvodnje derivata tienopirimidina
US10821152B2 (en) 2014-08-26 2020-11-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
ES2988678T3 (es) 2015-02-26 2024-11-21 Takeda Pharmaceuticals Co Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
CA3002791A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
US20180044977A1 (en) 2016-08-12 2018-02-15 Raynor Mfg. Co. Rolling door construction for controlling air leakage
EP3518932B1 (en) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Treatment of prostate cancer
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NCT02135445 ClinicalTrials.gov Archive, 2 June 2016 *
SHORE NEAL D ET AL: "PD28-01", JOURNAL OF UROLOGY, vol. 195(4S) page e654 (2016-05-08) *

Also Published As

Publication number Publication date
IL265697B1 (en) 2023-03-01
US20190224196A1 (en) 2019-07-25
EP4520398A3 (en) 2025-04-02
US12097198B2 (en) 2024-09-24
AU2023201047A1 (en) 2023-03-23
WO2018060463A2 (en) 2018-04-05
US20210205303A1 (en) 2021-07-08
US12336990B2 (en) 2025-06-24
AU2017334035A1 (en) 2019-05-16
AU2023201047B2 (en) 2025-04-03
FI3518932T3 (fi) 2025-02-03
EP3518932B1 (en) 2024-11-13
US20240358700A1 (en) 2024-10-31
US20220401443A1 (en) 2022-12-22
NZ752918A (en) 2022-09-30
US20200129507A1 (en) 2020-04-30
CN110248661A (zh) 2019-09-17
PT3518932T (pt) 2025-01-16
IL308528A (en) 2024-01-01
IL300071A (en) 2023-03-01
IL265697A (en) 2019-05-30
SI3518932T1 (sl) 2025-03-31
US10449191B2 (en) 2019-10-22
BR112019006228A2 (pt) 2019-06-18
US12144809B1 (en) 2024-11-19
LT3518932T (lt) 2025-02-10
HRP20241740T1 (hr) 2025-02-28
JP7062673B2 (ja) 2022-05-06
CA3038875A1 (en) 2018-04-05
MX2019003733A (es) 2019-09-26
EP4520398A2 (en) 2025-03-12
US10786501B2 (en) 2020-09-29
HUE070578T2 (hu) 2025-06-28
EP3518932A2 (en) 2019-08-07
IL265697B2 (en) 2023-07-01
US20250082632A1 (en) 2025-03-13
DK3518932T3 (da) 2025-01-27
JP2019529574A (ja) 2019-10-17
PL3518932T3 (pl) 2025-04-07
US11583526B2 (en) 2023-02-21
MX2023001468A (es) 2023-03-03
MA46361A (fr) 2021-03-31
US20250057839A1 (en) 2025-02-20
WO2018060463A3 (en) 2018-05-11
ES3002857T3 (en) 2025-03-07
US20250332166A1 (en) 2025-10-30

Similar Documents

Publication Publication Date Title
AU2023201047B2 (en) Treatment of prostate cancer
AU2022241582C1 (en) Methods of treating uterine fibroids and endometriosis
WO2001078686A1 (en) Time-release coated solid compositions for oral administration
JP2023096079A (ja) 化合物の製剤およびそれらの使用
HK40012835A (en) Treatment of prostate cancer
HK40012835B (en) Treatment of prostate cancer
HK40116485A (en) Treatment of prostate cancer
CN100589806C (zh) 类固醇衍生物在制备治疗血管紧张素ⅱ相关性疾病如心血管性和增生性疾病的药物中的应用
JPWO2009081837A1 (ja) 下部尿路症状の改善用医薬組成物
EA043716B1 (ru) Лечение рака предстательной железы
JP2023541423A (ja) Ｆｘｒアゴニストの固体分散体製剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: SUMITOMO PHARMA SWITZERLAND GMBH

Free format text: FORMER NAME(S): TAKEDA PHARMACEUTICAL COMPANY LIMITED; MYOVANT SCIENCES GMBH

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER NAME(S): TAKEDA PHARMACEUTICAL COMPANY LIMITED; MYOVANT SCIENCES GMBH